Levetiracetam in spinal cord injury pain: a randomized controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Levetiracetam in spinal cord injury pain: a randomized controlled trial. / Finnerup, N B; Grydehøj, J; Bing, J; Johannesen, I L; Biering-Sørensen, F; Sindrup, S H; Jensen, T S.

I: Spinal Cord, Bind 47, Nr. 12, 2009, s. 861-7.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Finnerup, NB, Grydehøj, J, Bing, J, Johannesen, IL, Biering-Sørensen, F, Sindrup, SH & Jensen, TS 2009, 'Levetiracetam in spinal cord injury pain: a randomized controlled trial', Spinal Cord, bind 47, nr. 12, s. 861-7. https://doi.org/10.1038/sc.2009.55

APA

Finnerup, N. B., Grydehøj, J., Bing, J., Johannesen, I. L., Biering-Sørensen, F., Sindrup, S. H., & Jensen, T. S. (2009). Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord, 47(12), 861-7. https://doi.org/10.1038/sc.2009.55

Vancouver

Finnerup NB, Grydehøj J, Bing J, Johannesen IL, Biering-Sørensen F, Sindrup SH o.a. Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord. 2009;47(12):861-7. https://doi.org/10.1038/sc.2009.55

Author

Finnerup, N B ; Grydehøj, J ; Bing, J ; Johannesen, I L ; Biering-Sørensen, F ; Sindrup, S H ; Jensen, T S. / Levetiracetam in spinal cord injury pain: a randomized controlled trial. I: Spinal Cord. 2009 ; Bind 47, Nr. 12. s. 861-7.

Bibtex

@article{d3fe553068a411df928f000ea68e967b,
title = "Levetiracetam in spinal cord injury pain: a randomized controlled trial",
abstract = "STUDY DESIGN: A randomized, double-blind, placebo-controlled, crossover, multicenter trial. A 1-week baseline period was followed by two treatment periods of 5 weeks duration with levetiracetam increased from 500 mg b.i.d. to a maximum of 1500 mg b.i.d. separated by a 1-week washout period. OBJECTIVES: The objective of the study was primarily to evaluate the efficacy of the anticonvulsant levetiracetam in patients with spinal cord injury (SCI) at- and below-level pain and secondarily to evaluate the effect on spasm severity. SETTING: Outpatients at two spinal cord units and a pain center. METHODS: Patients were allowed to continue their usual pain treatment at a constant dose. The primary outcome measure was the change in median daily pain score (on a 0-10 point numeric rating scale) from 1-week baseline period to the last week of each treatment period. Secondary outcome measures included pain relief of at- and below-level pain, allodynia, spasms and spasticity. RESULTS: A total of 36 patients with SCI at- and or below-level pain were enrolled. Of these, 24 patients completed the trial. We found no effect of levetiracetam on the primary (P=0.46) or any of the secondary outcome measures. Only two patients continued levetiracetam treatment following the trial, and one patient was still in levetiracetam treatment at the 6-month follow-up. Levetiracetam was generally well tolerated with no serious adverse events. CONCLUSIONS: Levetiracetam does not relieve neuropathic pain or spasm severity following spinal cord injury.",
author = "Finnerup, {N B} and J Grydeh{\o}j and J Bing and Johannesen, {I L} and F Biering-S{\o}rensen and Sindrup, {S H} and Jensen, {T S}",
note = "Keywords: Adult; Afferent Pathways; Aged; Analgesics; Anticonvulsants; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment (Health Care); Pain Measurement; Pain, Intractable; Parasympatholytics; Piracetam; Spasm; Spinal Cord; Spinal Cord Injuries; Treatment Failure",
year = "2009",
doi = "10.1038/sc.2009.55",
language = "English",
volume = "47",
pages = "861--7",
journal = "Spinal Cord",
issn = "1362-4393",
publisher = "nature publishing group",
number = "12",

}

RIS

TY - JOUR

T1 - Levetiracetam in spinal cord injury pain: a randomized controlled trial

AU - Finnerup, N B

AU - Grydehøj, J

AU - Bing, J

AU - Johannesen, I L

AU - Biering-Sørensen, F

AU - Sindrup, S H

AU - Jensen, T S

N1 - Keywords: Adult; Afferent Pathways; Aged; Analgesics; Anticonvulsants; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment (Health Care); Pain Measurement; Pain, Intractable; Parasympatholytics; Piracetam; Spasm; Spinal Cord; Spinal Cord Injuries; Treatment Failure

PY - 2009

Y1 - 2009

N2 - STUDY DESIGN: A randomized, double-blind, placebo-controlled, crossover, multicenter trial. A 1-week baseline period was followed by two treatment periods of 5 weeks duration with levetiracetam increased from 500 mg b.i.d. to a maximum of 1500 mg b.i.d. separated by a 1-week washout period. OBJECTIVES: The objective of the study was primarily to evaluate the efficacy of the anticonvulsant levetiracetam in patients with spinal cord injury (SCI) at- and below-level pain and secondarily to evaluate the effect on spasm severity. SETTING: Outpatients at two spinal cord units and a pain center. METHODS: Patients were allowed to continue their usual pain treatment at a constant dose. The primary outcome measure was the change in median daily pain score (on a 0-10 point numeric rating scale) from 1-week baseline period to the last week of each treatment period. Secondary outcome measures included pain relief of at- and below-level pain, allodynia, spasms and spasticity. RESULTS: A total of 36 patients with SCI at- and or below-level pain were enrolled. Of these, 24 patients completed the trial. We found no effect of levetiracetam on the primary (P=0.46) or any of the secondary outcome measures. Only two patients continued levetiracetam treatment following the trial, and one patient was still in levetiracetam treatment at the 6-month follow-up. Levetiracetam was generally well tolerated with no serious adverse events. CONCLUSIONS: Levetiracetam does not relieve neuropathic pain or spasm severity following spinal cord injury.

AB - STUDY DESIGN: A randomized, double-blind, placebo-controlled, crossover, multicenter trial. A 1-week baseline period was followed by two treatment periods of 5 weeks duration with levetiracetam increased from 500 mg b.i.d. to a maximum of 1500 mg b.i.d. separated by a 1-week washout period. OBJECTIVES: The objective of the study was primarily to evaluate the efficacy of the anticonvulsant levetiracetam in patients with spinal cord injury (SCI) at- and below-level pain and secondarily to evaluate the effect on spasm severity. SETTING: Outpatients at two spinal cord units and a pain center. METHODS: Patients were allowed to continue their usual pain treatment at a constant dose. The primary outcome measure was the change in median daily pain score (on a 0-10 point numeric rating scale) from 1-week baseline period to the last week of each treatment period. Secondary outcome measures included pain relief of at- and below-level pain, allodynia, spasms and spasticity. RESULTS: A total of 36 patients with SCI at- and or below-level pain were enrolled. Of these, 24 patients completed the trial. We found no effect of levetiracetam on the primary (P=0.46) or any of the secondary outcome measures. Only two patients continued levetiracetam treatment following the trial, and one patient was still in levetiracetam treatment at the 6-month follow-up. Levetiracetam was generally well tolerated with no serious adverse events. CONCLUSIONS: Levetiracetam does not relieve neuropathic pain or spasm severity following spinal cord injury.

U2 - 10.1038/sc.2009.55

DO - 10.1038/sc.2009.55

M3 - Journal article

VL - 47

SP - 861

EP - 867

JO - Spinal Cord

JF - Spinal Cord

SN - 1362-4393

IS - 12

ER -

ID: 19977643